Drug Trial Radar · NCT00144261
An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects
Last checked: Nov 20, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Nov 1, 2003
Primary completion
Dec 1, 2006
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. In order to obtain further insight as to how NVP affects HDL metabolism, the in vivo kinetics of the HDL apolipoprotein, Apo A-1, before and 6 weeks after initiation of NVP containing treatment were evaluated. In addition, the activity of the key enzymes related to HDL metabolism were assessed. \[ Designated as safety issue: No \] 2. In order to determine the relevance of the HDL increase in decreasing cardiovascular risk in HIV-positive subjects we evaluated endothelial function (FMD) as a surrogate marker for cardiovascular disease in patients. \[ Designated as safety issue: No \]
Conditions
- HIV Infections
- Metabolism, Lipids
Interventions
nevirapineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change of fractional synthetic rate (FSR) of Apo A-1Time frame: after 6 weeks of treatment
- Percentage change of flow mediated dilatation (FMD)Time frame: after 6 and 24 weeks of treatment
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
1100.1426.01 Academic Medical Centre
Amsterdam, Netherlands
1100.1426.02 Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands
1100.1426.44001 Boehringer Ingelheim Investigational Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.